Director, Head of Research, Smartkarma

Pranav Rao

Director, Head of Research

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Event-Driven

<ul>
<li>Welcome to Curator’s Cut - a fortnightly roundup of standout themes from the 1,400+ insights shared on Smartkarma.</li>
<li>In this cut, we look at where value remains in a difficult year for luxury, review momentum in offshore services, and assess two sides of the insurance sector. </li>
<li>Want to dig deeper? Comment or message with the themes you'd like to see highlighted next.</li>
</ul>


Welcome to Curator’s Cut - a fortnightly roundup of standout themes from the 1,400+ insights shared on Smartkarma.
In this cut, we look at where value remains in a difficult year for luxury, review momentum in offshore services, and assess two sides of the insurance sector. 
Want to dig deeper? Comment or message with the themes you'd like to see highlighted next.


Curator's Cut: Luxury Losing Lustre, Offshore Revived & Insurance's Two Sides

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Biotech remains the IPO market’s lone bright spot, with TRex Bio testing investor appetite as broader September IPOs struggled and Oura postponed. </li>
<li>TRex Bio is seeking $117–$133 million at a $384–$439 million valuation, backed by a Phase 1 lead program and a Lilly collaboration. </li>
<li>Lilly provides a significant validation signal, with a 23.9% pre-IPO stake and TRex Bio eligible for up to $577.5 million in additional milestones plus royalties.</li>
</ul>


Biotech remains the IPO market’s lone bright spot, with TRex Bio testing investor appetite as broader September IPOs struggled and Oura postponed. 
TRex Bio is seeking $117–$133 million at a $384–$439 million valuation, backed by a Phase 1 lead program and a Lilly collaboration. 
Lilly provides a significant validation signal, with a 23.9% pre-IPO stake and TRex Bio eligible for up to $577.5 million in additional milestones plus royalties.


TRex Bio (TRXB): Biotech Sector Remains Open as Lilly Backed Bio Sets Terms for IPO

Bamboo Insurance Services / Equity Capital Markets

<ul>
<li>Bamboo’s IPO has a rosy-colored picture of demand, but valuation feedback remains critical ahead of Tuesday’s pricing.</li>
<li>Strong growth, a 44% adjusted EBITDA margin and capital-light MGA model support the story, while Texas expansion provides a new growth avenue.</li>
<li>Orion180’s below-range pricing highlights insurance IPO price sensitivity, making Bamboo’s final valuation and secondary structure key investor considerations.</li>
</ul>


Bamboo’s IPO has a rosy-colored picture of demand, but valuation feedback remains critical ahead of Tuesday’s pricing.
Strong growth, a 44% adjusted EBITDA margin and capital-light MGA model support the story, while Texas expansion provides a new growth avenue.
Orion180’s below-range pricing highlights insurance IPO price sensitivity, making Bamboo’s final valuation and secondary structure key investor considerations.


Bamboo Insurance Services (BMB): Strong Growth, But Will Investors Pay Up?

United States

Orion180 is a leading insurance provider offering innovative, tech-driven homeowners, flood, and property insurance solutions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Orion180 Insurance Group (OIG US)

Curator's Cut: Luxury Losing Lustre, Offshore Revived & Insurance's Two Sides

In this Curator's Cut, we survey luxury's retreat, revisit offshore services, and assess differing drivers in insurance from policy headwinds to...

Pranav Rao

TRex Bio (TRXB): Biotech Sector Remains Open as Lilly Backed Bio Sets Terms for IPO

TRex Bio brings a Treg-focused biotech platform to market with a Phase 1 lead asset, strong existing investors and Eli Lilly backing as biotech...

IPO Boutique

Bamboo Insurance Services (BMB): Strong Growth, But Will Investors Pay Up?

Bamboo’s strong growth and 44% EBITDA margin drive demand, but comp Orion180’s weak pricing keeps valuation front and center as investors assess...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)